2,8-bis(trifluoromethyl)-α-cyclohexyl-4-quinolinemethanol | 260971-99-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,8-bis(trifluoromethyl)-α-cyclohexyl-4-quinolinemethanol
• 英文别名: [2,8-Bis(trifluoromethyl)quinolin-4-yl]-cyclohexylmethanol
• CAS: 260971-99-1
• 化学式: C₁₈H₁₇F₆NO
• 分子量: 377.329
• InChiKey: UYQZAZBTVUFPHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (I)
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1107760A2

  公开（公告）日：2001-06-20
• US6583156B1
  申请人：——

  公开号：US6583156B1

  公开（公告）日：2003-06-24
• [EN] 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (I)<br/>[FR] DERIVES DE 4-QUINOLINEMETHANOL UTILISES COMME ANTAGONISTES (I) DU RECEPTEUR DE PURINE
  申请人：CEREBRUS PHARM LTD

  公开号：WO2000013681A2

  公开（公告）日：2000-03-16

  Use of a compound of formula (I): Wherein: R1 is hydrogen or alkyl; R2 and R3 are independently selected from hydrogen, alkyl, aryl and heterocycyll or together may form a ring or R1 and R2 or R3 together may form a oxygen-containing, optionally fused ring pharmaceutically acceptable salts or prodrugs thereof, with the proviso that where R1 and R4 to R9 are hydrogen, R2 or R3 is not 3-methoxy-4-benzyloxyphenyl or 2- dimethylaminoethoxymethyl, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial. Said disorders are neurodegenerative disorders or movement disorders selected from Parkinson disease or progressive supemuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.